PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TUBERCULOSIS
申请人:INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
公开号:US20150133503A1
公开(公告)日:2015-05-14
The present invention relates to a pharmaceutical composition for preventing or treating tuberculosis, comprising: (a) a pharmaceutically effective amount of a compound represented by the following chemical formula 1; and (b) a pharmaceutically acceptable carrier. Chemical formula 1 The compound contained as an active ingredient of the present invention inhibits the expression and activity of CO-DH in tubercle
bacillus
so as to effectively block the detoxification of carbon monoxide, which is an important survival factor of tubercle
bacillus
, and is safe for the human body since the compound targets CO-DH which does not exist in the human body. In addition, the compound creates a synergistic effect when combined with a conventional tuberculostatic drug, and thus can be more effective for treating tuberculosis.
US9364468B2
申请人:——
公开号:US9364468B2
公开(公告)日:2016-06-14
[EN] N-PHENYLAMIDE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES COMPRISING SAME<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉES DE N-PHÉNYLAMIDE ET COMPOSITION PRÉVENANT OU TRAITANT LES TROUBLES ISCHÉMIQUES LES COMPRENANT
申请人:KOREA RES INST CHEM TECH
公开号:WO2008069611A1
公开(公告)日:2008-06-12
[EN] The present invention relates to a compound of Formula I, a process for the preparation thereof, and a composition for preventing or treating an ischemic disease comprising a compound of Formula I' as an effective ingredient. Since the N-phenylamide derivatives of the present invention can significantly reduce ischemic cell death, they can be effectively used for preventing or treating ischemic diseases mediated by ischemic cell death, or for protecting organs. [FR] L'invention porte sur un composé de formule (I), sur son procédé de préparation, et sur une composition prévenant ou traitant les troubles ischémiques dont le composé de formule (I) constitue le principe actif. Comme les dérivées de N-phénylamide de l'invention peuvent significativement réduire la mort cellulaire ischémique, ils peuvent être efficacement utilisés pour prévenir ou traiter les troubles ischémiques médiés par la mort cellulaire ischémique, ou pour protéger des organes.